The CU Thoracic Oncology Program has been behind almost every major development in the treatment of thoracic cancers, particularly lung cancer, in the last decade. In addition to research ideas originating directly from CU, as our national and international reputation has grown to make us one of the top lung cancer programs in the world, we get offered a very wide array of new drugs and new approaches to explore in clinical trials. We then use our extensive experience to try to pick the experimental drugs and treatments with the very highest chances of success to include in our clinical trials portfolio. Nationally only about 3% of lung cancer patients are placed on clinical trials, but for many years our own accrual rates have consistently run at about 40% - one of the highest in the world - not because we are in the business of throwing trials at people, but much more because we believe the best treatment for many cancers continues to improve and clinical trials are the means to get our patients access to these potential breakthroughs years before they will become more widely available.